Cellebrite DI

Valuation Analysis

About the Company

Cellebrite DI en bref

Cellebrite DI (CLBT) is currently trading at 11,20 € with a market capitalization of 2,8 Md €. The trailing P/E ratio stands at 45.82x, with a forward P/E of 19.41x. The 52-week range spans from 9,62 € to 17,44 €; the current price is 35.8% below the yearly high. Year-over-year revenue growth stands at +19.3%. The net profit margin stands at 14.48%.

💰 Dividende

Cellebrite DI currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Cellebrite DI (CLBT) au consensus : Achat Fort. L'objectif de cours moyen est de 18,33 €, soit un potentiel de +63.68% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,09 € à 24,43 €.

Cellebrite DI : la thèse d'investissement en détail

Cellebrite DI (CLBT) operates in the Technology — specifically Software - Infrastructure — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 19.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 83.86%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 63.68% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 34.57x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 19.41x is meaningfully below the trailing 45.82x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 63.68% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Cellebrite DI?

Compare top-rated brokers — low fees, trusted providers, fully regulated.